Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study
- 13 October 2017
- journal article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 46 (11-12), 1077-1084
- https://doi.org/10.1111/apt.14371
Abstract
Anti-tumour necrosis factor (TNF) agents have improved the care of Crohn's disease (CD). After the first anti-TNF discontinuation, it is possible to switch to another anti-TNF. Three anti-TNF agents are available for ulcerative colitis (infliximab, adalimumab and golimumab), but only the first 2 have been approved for CD because golimumab has not been studied for this indication. To report the efficacy and safety of golimumab in CD. Crohn's disease patients who received golimumab were identified in 12 French tertiary centres and were retrospectively analysed. The primary endpoint was the duration of golimumab treatment before escalation or discontinuation. The clinical response was defined as a decrease of more than 3 points in the Harvey-Bradshaw index or by global physician assessment. One hundred and fifteen patients were included. The golimumab treatment duration was 9.8 months (0.55-44), and 48.7% of the patients were still under treatment at the end of follow-up. Clinical response was observed in 55.8% of the patients after a mean duration of 3.8 months. The probability of remaining under treatment without escalation at 6, 12 and 24 months was 54.6%, 34.9% and 19.3% respectively. In multivariate analysis, discontinuation of the first anti-TNF agent due to intolerance (odds ratio, OR = 2.16; 95% CI, confidence interval [1.25-3.86]; P = .005) and co-immunosuppression for more than 6 months (OR = 3.98; 95% CI [2.3-7.1]; P < .0001) were predictive factors of efficacy. Six per cent of the patients discontinued treatment due to intolerance. After failure of infliximab or adalimumab for Crohn's disease, golimumab was safe and seemed beneficial in half of the patients.Keywords
This publication has 23 references indexed in Scilit:
- Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trialThe Lancet, 2015
- Systematic review with meta‐analysis: the efficacy of a second anti‐TNF in patients with inflammatory bowel disease whose previous anti‐TNF treatment has failedAlimentary Pharmacology & Therapeutics, 2015
- Benefit of Infliximab Reintroduction after Successive Failure of Infliximab and Adalimumab in Crohn's DiseaseJournal of Crohn's and Colitis, 2014
- Pharmacokinetics of Adalimumab in Inflammatory Bowel DiseasesInflammatory Bowel Diseases, 2014
- Optimizing anti-TNF treatments in inflammatory bowel diseaseAutoimmunity Reviews, 2014
- Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-AnalysisAmerican Journal of Gastroenterology, 2013
- Anti-TNF antibody therapy in Crohn's disease: the risk of a switchGut, 2011
- Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic ReviewAmerican Journal of Gastroenterology, 2011
- Review article: loss of response to anti-TNF treatments in Crohn’s diseaseAlimentary Pharmacology & Therapeutics, 2011
- The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximabAlimentary Pharmacology & Therapeutics, 2010